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A B S T R A C T
Low-density lipoprotein (LDL) modiﬁed by hypochlorous acid (HOCl) produced by myeloperoxidase (MPO) is
present in atherosclerotic lesions, where it is implicated in the propagation of inﬂammation and acceleration of
lesion development by multiple pathways, including the induction of endothelial dysfunction. Thiocyanate
(SCN-) ions are utilised by MPO to produce the oxidant hypothiocyanous acid (HOSCN), which reacts with LDL
in a diﬀerent manner to HOCl. Whilst the reactivity of HOCl-modiﬁed LDL has been previously studied, the role
of HOSCN in the modiﬁcation of LDL in vivo is poorly deﬁned, although emerging evidence suggests that these
particles have distinct biological properties. This is important because elevated plasma SCN- is linked with both
the propagation and prevention of atherosclerosis. In this study, we demonstrate that both HOSCN- and HOCl-
modiﬁed LDL inhibit endothelium-mediated vasorelaxation ex vivo in rat aortic ring segments. In vitro experi-
ments with human coronary artery endothelial cells show that HOSCN-modiﬁed LDL decreases in the production
of nitric oxide (NO•) and induces the loss of endothelial nitric oxide synthase (eNOS) activity. This occurs to a
similar extent to that seen with HOCl-modiﬁed LDL. In each case, these eﬀects are related to eNOS uncoupling,
rather than altered expression, phosphorylation or cellular localisation. Together, these data provide new in-
sights into role of MPO and LDL modiﬁcation in the induction of endothelial dysfunction, which has implications
for both the therapeutic use of SCN- within the setting of atherosclerosis and for smokers, who have elevated
plasma levels of SCN-, and are more at risk of developing cardiovascular disease.
1. Introduction
Atherosclerosis is the primary underlying pathology of most cardi-
ovascular diseases. The initial stages of the disease are characterised by
loss of endothelial function [1] and chronic inﬂammation [2], which is
coupled with the accumulation of low density lipoprotein (LDL) in the
arterial intima [3]. It is well documented that LDL oxidation plays a key
role in promoting lesion development in atherosclerosis via a number of
pathways (reviewed [3,4]). In addition to the well-deﬁned recognition
of oxidised LDL (oxLDL) by various scavenger receptors, which leads to
the formation of lipid-laden “foam cells”, there is strong evidence to
show a role of oxLDL as a mediator of endothelial dysfunction via its
action on endothelial nitric oxide synthase (eNOS), which perturbs ni-
tric oxide (NO•) bioavailability both in vitro [5–7] and ex vivo [8–10].
The formation of NO• by eNOS is dependent on both the dimeric
structure of the enzyme and the binding of multiple co-factors and sub-
units, including zinc, tetrahydrobiopterin (BH4), and calcium-bound
calmodulin (CaM) [11]. Uncoupling and disruption to the structure of
eNOS therefore leads to a depletion in bioavailable NO• and subsequent
endothelial dysfunction [12]. This has been implicated as a key
pathway to impair arterial distensibility in atherosclerosis, given the
potent vasodilatory properties of NO• [13]. In addition to uncoupling,
http://dx.doi.org/10.1016/j.redox.2017.08.004
Received 3 July 2017; Accepted 4 August 2017
⁎ Corresponding author at: Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen N, Denmark.
E-mail address: clare.hawkins@sund.ku.dk (C.L. Hawkins).
Abbreviations: ACh, acetylcholine; ApoB100, apolipoprotein B100; B2M, β2-microglobulin; BH4, tetrahydrobiopterin; CaM, calmodulin; DHE, dihydroxyethidine; E+, ethidium; eNOS,
endothelial nitric oxide synthase; EPR, electron paramagnetic resonance; FAD, ﬂavin adenine dinucleotide; FMN, Flavin mononucleotide; HOCl, hypochlorous acid; HOSCN, hy-
pothiocyanous acid; HCAEC, human coronary artery endothelial cells; HUVEC, human umbilical vein endothelial cells; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; L-NIO,
N5-(1-iminoethyl)-L-ornithine; MGD, N-methyl-D-glucamine dithiocarbamate; MPO, myeloperoxidase; MAPK, mitogen-activated protein kinase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; NADPH, nicotinamide adenine dinucleotide phosphate; NE, norepinephrine; NO•, nitric oxide; 2-OH-E+, 2-hydroxyethidium; O2•-, superoxide; oxLDL,
oxidised low-density lipoprotein; PKC, protein kinase C; RIPA, radioimmunoprecipitation assay; RT-PCR, real-time polymerase chain reaction; SCN-, thiocyanate ions; SNP, sodium
nitroprusside; TBS, tris-buﬀered saline; TNB, 5-thio-2-nitrobenzoic acid; 13-HPODE, 13-hydroperoxyoctadecadienoate; 18S, 18S ribosomal RNA
Redox Biology 13 (2017) 623–632
Available online 05 August 2017
2213-2317/ © 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
MARK
eNOS activity can be inﬂuenced by disruption of CaM binding by sev-
eral factors, including caveolin-1, which binds to eNOS and prevents L-
Arg catalysis to L-citrulline and hence NO• production [14]. The pro-
duction of NO• by eNOS is also regulated by a series of complex post-
translational modiﬁcations, including phosphorylation, acylation, S-
nitrosylation, and acetylation [11,15]. Similarly, alterations in the sub-
cellular localisation of eNOS can perturb the production of NO• by en-
dothelial cells in vitro [5,6].
Although it is well accepted that oxLDL can perturb endothelial NO•
production, the speciﬁc pathways responsible are deﬁned by the nature
of the oxidising system responsible for the modiﬁcation of LDL, and the
type of endothelial cell under study (e.g. [5,6,16–18]). This may be
related, at least in part, to the pattern of oxidation on the LDL, which
can diﬀer widely between oxidants [3,4]. There is some debate as to the
most relevant type of oxLDL to use as a model in studies relating to
atherosclerosis. The most commonly studied oxLDL is generated via
incubation of native LDL with Cu2+ ions, which forms a highly-mod-
iﬁed particle with extensive lipid oxidation. The relevance of this type
of LDL to atherosclerosis has been questioned, largely due to the
marked diﬀerence in magnitude between the concentration of Cu2+
used to modify LDL in vitro, compared to that measured in diseased
tissue [3,19].
Human atherosclerotic lesions contain elevated amounts of proteins
that have been modiﬁed by the oxidant hypochlorous acid (HOCl) [20],
including LDL [21]. This oxidant is produced by the enzyme myelo-
peroxidase (MPO), which is also elevated in diseased tissue [22] and is
recognised as both a risk factor for the development of coronary artery
disease and prognostic agent for patient outcome following diﬀerent
cardiac events (reviewed [23]). It is also reported that the presence of
HOCl-modiﬁed proteins correlates with intimal thickening in athero-
sclerotic plaques and apolipoprotein content [24]. Additionally, the
cationic MPO has an aﬃnity for non-covalent binding to the pre-
dominantly anionic LDL to form a complex [25], which has also been
shown to augment the chlorinating activity of MPO in vitro [26]. Im-
portantly, MPO-LDL complexes are present in the circulation of patients
with atherosclerosis, further supporting the in vivo relevance of this
type of modiﬁed LDL [27].
There is signiﬁcant evidence that the modiﬁcation of LDL by HOCl
promotes atherogenesis (reviewed [28,29]). There are in vitro studies
that provide support for the induction of endothelial dysfunction by
HOCl-modiﬁed LDL, with evidence for reduced NO• production by de-
localisation of the eNOS in human umbilical vein endothelial cells
(HUVEC) [5]. Similarly, the ability of RAW 264.7 murine macrophages
to produce NO• following stimulation with LPS was compromised fol-
lowing exposure to HOCl-LDL [30]. In contrast, there are rather limited
data regarding the biological reactivity of LDL modiﬁed by hypothio-
cyanous acid (HOSCN), which is the other major MPO-derived oxidant
formed under normal physiological conditions [31]. This is signiﬁcant
because there are conﬂicting data regarding the role of thiocyanate
(SCN-), which is the precursor to HOSCN, in the development of
atherosclerosis [32].
Smoking results in elevated blood SCN- levels and a higher in-
cidence of cardiovascular disease [33]. Similarly, serum SCN- levels in
smokers correlate with a higher deposition of oxidised LDL and fatty
streak formation in the arteries [34,35]. However, supplementation of
transgenic, atherosclerosis-prone, mice that over-express human MPO,
with SCN- resulted in a decreased extent of lesion formation [36]. The
reactivity of HOCl and HOSCN are strikingly diﬀerent [37], which re-
sults in the formation of modiﬁed LDL particles that have distinct cel-
lular eﬀects [27,38,39]. In light of these conﬂicting data, and given the
importance of endothelial dysfunction in the pathogenesis of athero-
sclerosis, we performed experiments to assess the eﬀect of HOCl- and
HOSCN-modiﬁed LDL on endothelium-dependent vasorelaxation ex
vivo, using pre-constricted rat aortic segments and on the production of
NO• and eNOS functionality in vitro using human coronary artery en-
dothelial cells (HCAEC).
2. Materials and methods
2.1. Materials and reagents
All Chemicals were purchased from Sigma-Aldrich unless stated
otherwise. All aqueous reagents were prepared with nanopure water
from a four stage-ﬁltered Milli-Q water system. PBS (Amresco) was
treated with Chelex-100 (BioRad) for 2 h to remove trace transition
metal ions, prior to ﬁlteration and re-adjusting the pH to 7.4 with HCl.
HOCl was prepared in PBS by dilution of a NaOCl stock solution (BDH),
quantiﬁed at 292 nm (ε292 = 350 M−1 cm−1) at pH 11 [40]. HOSCN
was synthesised enzymatically using lactoperoxidase (LPO; from bovine
milk; Calbiochem) as described previously [41] and used immediately
following quantiﬁcation with 5-thio-2-nitrobenzoic acid (TNB) at
412 nm (ε412 = 14150 M−1 cm−1) [42,43].
2.2. Isolation and oxidation of human LDL from plasma
Human blood was taken by a qualiﬁed phlebotomist with the do-
nor’s consent and under ethics approval (Sydney Local Health District,
protocol X12-0375) in accordance with the Declaration of Helsinki,
2000 of the World Medical Association. LDL (ρ 1.019–1.050 kg L−1)
was isolated from plasma using sequential density gradient ultra-
centrifugation (Optima™ XPN; Beckman) as previously described [44]
before four changes of dialysis into PBS containing 0.1 mg mL−1
chloramphenicol and 1 mg mL−1 EDTA (Astral Scientiﬁc) and stored at
4 °C in the dark. LDL was adjusted to a concentration of 1.0 mg mL−1
apoB100 following desalting through a PD-10 column (GE Healthcare)
to remove chloramphenicol and EDTA and incubation with HOCl or
HOSCN (100–250 μM) at 37 °C for 24 h. A control LDL sample was
incubated under the same conditions without oxidant (control LDL). A
minimum of 3 independent LDL donors were used in all experiments.
2.3. Ex vivo rat aortic ring studies of vasodilation
The thoracic aortae were harvested from 5 Sprague Dawley male
rats (~ 150–250 g) and rapidly cleaned and stripped of fat and adhered
tissue in Hanks balanced salt solution (HBSS) with Royal Prince Alfred
Hospital Animal Ethics Committee approval (protocols # 2014-020,
2014-030 and 2014-040). The thoracic aorta was cut into 4 mm lengths
before mounting in 7 mL myograph chambers (Danish Myo Technology,
Aarhus, Denmark) containing HBSS and maintained at 37 °C and pH 7.4
by continuous bubbling with 95% O2 and 5% CO2. Aortic segments
were washed with HBSS before treatment with each preparation of LDL
(0.1 mg mL−1) for 1 h at 37 °C. The segments were washed with HBSS
before measurement of the vasoconstrictive dose-response to nor-
epinephrine (NE; 10−9–10−5 M). The dilatory response of 80% nor-
epinephrine pre-constricted rings to incremental doses of acetylcholine
(ACh; 10−8–10−3 M) or endothelium-independent sodium nitroprus-
side (SNP; 10−9–10−5 M) was determined for each LDL treatment.
2.4. Cell culture and viability
Human coronary artery endothelial cells (HCAEC) from 3 in-
dependent donors were cultured using MesoEndo Endothelial Cell
Growth Media (Cell Applications) and used between passages 4–6.
HCAEC were dissociated with 0.1% (w/v) trypsin-EDTA for 1 min at
37 °C before deactivation of trypsin with growth media. Cells were
pelleted by centrifugation (5 min at ~ 232g), aspirated, resuspended in
media before seeding overnight at a density of 0.5 × 105 cells mL−1 in
tissue culture plates. Cells were washed twice with PBS before in-
cubation with the diﬀerent LDL preparations at a concentration of
0.1 mg mL−1 apoB100 protein in serum-free deﬁned media supple-
mented with 5% foetal bovine serum. Cell viability and metabolic ac-
tivity were measured by the lactate dehydrogenase (LDH) assay and 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
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assay respectively, as previously [44,45].
2.5. Quantiﬁcation of NO• production
The release of NO• from HCAEC following treatment with each LDL
preparation was assessed by electron paramagnetic resonance (EPR)
spectroscopy using the Fe(II) chelate spin trap N-methyl-D-glucamine
dithiocarbamate (MGD) [46]. HCAEC were treated with each LDL
preparation for 24 h before washing and incubation at 37 °C for 36 min
with Fe(II)-MGD, which was prepared immediately before adding to
cells by mixing degassed solutions of FeSO4 and MGD (both 0.95 mM).
The release of NO• into the cell media was then assessed using an X-
band EMXplus EPR spectrometer (Bruker) and Xenon software with the
following parameters: frequency: 9.8 GHz; centre ﬁeld: 342 mT; mod-
ulation amplitude: 0.6 mT; sweep width: 10 mT; power: 25 mW. Signal
intensity was quantiﬁed by double-integration of the signal from 338.7
to 345.2 mT. Cells were treated with N5-(1-iminoethyl)-L-ornithine (L-
NIO, 100 µM) for 1 h prior to the addition of Fe(II)-MGD to assess eNOS
independent NO• production.
2.6. Measurement of eNOS activity using 3H citrulline
HCAEC eNOS activity was measured using the NOS activity assay
(Cayman Chemicals) following treatment of the HCAEC in 60 mm petri
dishes for 24 h prior to dissociation in PBS containing 1 mM EDTA for
5 min at 37 °C. The cell suspension was then pelleted by centrifugation,
before lysis with homogenisation buﬀer and normalisation of the pro-
tein concentration to 0.5 mg mL−1 following BCA assay [44]. 5 μL of
each sample was added to a 25 mM Tris-HCl reaction buﬀer containing
1 μL 3H-arginine (1 μCi μL−1), 750 μM CaCl2, 3 μM tetra-
hydrobiopterin, 1 μM ﬂavin adenine mononucleotide and dinucleotide
(FAD and FMN), 2 mM NADPH and 0.2 μM calmodulin, then incubated
for 1 h at 21 °C. Reaction stopping buﬀer (400 μL, 50 mM HEPES, 5 mM
EDTA, pH 5.5) was added before separating unreacted 3H-arginine from
3H-citrulline product using an equilibrated resin and eluting 3H-citrul-
line through a spin cup (22,000g for 30 s). Eluate (200 μL) was trans-
ferred to a scintillation vial, mixed with 5 mL scintillation ﬂuid and
scintillation was measured using a liquid scintillation counter (Perkin
Elmer). Total and background scintillation controls were also per-
formed to calculate the percentage 3H-citrulline conversion.
2.7. RNA isolation and RT-PCR
HCAEC were plated in 12-well plates overnight prior to the addition
of LDL or modiﬁed LDL and further incubated for 3 or 24 h. RNA ex-
traction was performed using the Promega Reliaprep RNA Miniprep Kit
using the manufacturer’s protocol with a 45 min DNase step. The RNA
concentration of each sample was measured using a Nanodrop 2000C
spectrophotometer (Thermo Scientiﬁc) before normalizing to
5–10 µg mL−1. Reverse transcription was performed using the iScript
cDNA synthesis kit and the Eppendorf Mastercycler 2 per manu-
facturer’s instructions (BioRad). The gene expression of eNOS was
measured by quantitative real-time polymerase chain reaction (qRT-
PCR) and normalised to 18S ribosomal RNA (1818S) and β2-micro-
globulin (B2M) housekeeping genes with the following primer se-
quences (5′- to −3′): eNOS, forward: GGATCCAGTGGGGGAAACTG,
reverse: TGGCTGAACGAAGATTGCCT, 18S, forward: GAGG
ATGAGGTGGAACGTGT, reverse: TCTTCAGTCGCTCCAGGTCT and
B2M, forward: TGTCTC AGTTCCACCCACCT, reverse:
ATTACATGTCTCGGTCCCAGG. All primers were designed using NCIB
software and synthesised by GeneWorks. Quantitative RT-PCR was
performed with the iQ SYBR Green supermix as per the manufacturers’
instructions (BioRad). Gene expression was measured using the Pfaﬄ
method [47].
2.8. Western blot and eNOS protein-protein interactions by co-
immunoprecipitation
For immunoprecipitation of eNOS, 1 µg of eNOS antibody (BD
Bioscience; cat. # 610297) was incubated with 30 mg of Dynabeads®
protein G (cat. # 10003D; Life Technologies) for 20 min at 21 °C. Whole
cell pellets were lysed in tris-buﬀered saline (TBS) and 0.1% v/v Triton
X-100, then sonicated to dislodge eNOS from the plasma membrane.
Immunoprecipitation was then carried out per manufacturer’s instruc-
tion. HCAEC eNOS-immunoprecipitate and the immunoprecipitate su-
pernatant were stored on ice until separation of whole cell lysate or
supernatant, and total eNOS immunoprecipitated (10 µg) by SDS-PAGE.
For eNOS uncoupling, HCAEC were treated as previously described for
24 h before being lysed with radioimmunoprecipitation assay (RIPA)
buﬀer supplemented with protease inhibitor cocktail (cat. # P8340;
Sigma-Aldrich) and phosphatase inhibitors (PhosStop; Roche). Samples
(20 µg protein) were separated by SDS-PAGE at 120 V for approxi-
mately 1.5 h in an ice bath to minimise thermal uncoupling of eNOS.
The proteins were transferred to a PVDF membrane using an iBlot 2
system (Life Technologies). Membranes were blocked with 5% (w/v)
bovine serum albumin in TBS with 0.1% v/v Tween-20 overnight at
4 °C. Blots were incubated with 1:1000 anti-eNOS, anti-(pS1177)-eNOS,
(BD Bioscience; cat. # 612393), or (1:2000) β-actin (Santa Cruz; cat #
sc-47778) for 2 h at 21 °C. The secondary IgG-HRP-conjugated antibody
(Cell Signalling Technologies; cat. # 7076) was added (dilution 1:2000)
for 1 h at 21 °C. Chemiluminescence was induced with the enhanced
chemiluminescence substrate (Perkin Elmer) and imaged with a
ChemiDoc MP (BioRad) imaging system.
2.9. Quantiﬁcation O2•- using dihydroethidium by HPLC
After treatment, freshly prepared dihydroethidium (DHE, 50 μM)
was added to the HCAEC for 30 min at 37 °C. Cells were removed from
the plate after washing by addition of cold PBS and gentle scraping,
before precipitation of the proteins and preparation of samples for
HPLC analysis as described previously [48]. Separation of 2-hydro-
xyethidium (2-OH-E+) and ethidium (E+) from parent DHE was per-
formed using a Synergi Polar RP C18 column (250 × 4.6 mm, 4 µM,
80 Å; Phenomenex), equilibrated with 60% mobile phase A (10%
CH3CN in 50 mM potassium phosphate buﬀer pH 2.6) and 40% mobile
phase B (60% CH3CN in 50 mM potassium phosphate buﬀer pH 2.6)
with a linear increase to 100% mobile phase B over 63 min at a ﬂow
rate of 0.5 mL min−1 using a Shimadzu LC-10AT liquid chromatograph
system [48]. Products were quantiﬁed by ﬂuorescence (DHE; λex
358 nm, λem 440 nm, and 2-OH-E+ and E+; λex 490 nm, λem 565 nm).
The concentration of 2-OH-E+ was normalised to cell protein con-
centration.
2.10. Statistical analyses
Data are expressed as mean± standard error of the mean (SEM)
from at least 3 independent experiments, with statistical analyses per-
formed using either one-way or two-way ANOVA with appropriate post-
hoc tests as detailed in the Figure Legends (GraphPad Prism 7,
GraphPad Software, San Diego, USA), with p< 0.05 taken as sig-
niﬁcant.
3. Results
3.1. Eﬀect of modiﬁed LDL on endothelium-dependent vasorelaxation ex
vivo
The reduction of eNOS activity and subsequent decreased production
of NO• in vivo is a key pathway to endothelial dysfunction in athero-
sclerosis, therefore initial studies were performed to examine the eﬀect of
HOCl- and HOSCN-modiﬁed LDL on vasorelaxation using pre-constricted
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rat aortic segments. Aortic rings were constricted with norepinephrine
(10−9–10−5 M) and dilated with increasing concentrations of acetylcho-
line (10−8–10−3 M), to enable assessment of the return to baseline ten-
sion, measured by myography (Fig. 1A). Treatment of the aortic rings with
HOSCN- or HOCl-modiﬁed LDL (0.1 mg mL−1) for 1 h resulted in a sig-
niﬁcant decrease in pre-constricted vessel relaxation in response to acet-
ylcholine (Emax 60%) compared to the non-treated aortic rings (Emax 94%)
in each case (Fig. 1B).
A decrease in vessel relaxation was also observed in experiments
with the control LDL, but in this case, the decrease was less pronounced
(Emax 80%), and not statistically signiﬁcant compared control aortic
rings (Fig. 1B). In contrast, the endothelium-independent vasorelaxa-
tion responses as assessed by addition of sodium nitroprusside
(10−9–10−5 M) to pre-constricted rings were not signiﬁcantly diﬀerent
between the control and all LDL treatments (control: 99.4%, control
LDL: 99.5%, HOSCN-modiﬁed LDL: 93.3% and HOCl-modiﬁed LDL:
98.8%; Fig. 1C). This suggests that the eﬀect of HOCl and HOSCN-
modiﬁed LDL on the aortic ring relaxation is related to its eﬀects on the
endothelium, therefore further in vitro experiments were performed
with HCAEC to examine the cellular mechanism involved.
3.2. Eﬀect of modiﬁed LDL on NO• production and eNOS activity in HCAEC
HCAEC (0.5 × 105 cells mL−1) were treated with each modiﬁed
LDL (0.1 mg mL−1) for 24 h before addition of the Fe(II) chelate spin
trap MGD and assessment of NO• production by EPR spectroscopy.
Exposure of HCAEC to LDL modiﬁed by either HOCl or HOSCN
(100–250 μM) resulted in a signiﬁcant decrease in the intensity of the
Fe-MGD-NO adduct compared to the non-treated cells (Figs. 2A, C).
This is consistent with a decrease in NO• production by the cells. A loss
in EPR signal intensity was also observed in the analogous experiments
with the incubation control LDL, which could be associated with oxi-
dation of the LDL during the incubation conditions either before or after
addition to the HCAEC. The contribution of eNOS activity in HCAEC to
the formation of the Fe-MGD-NO adduct was veriﬁed by pre-treatment
of the HCAEC with the eNOS inhibitor with L-NIO (100 µM), which
almost completely ablated the EPR signal (Fig. 2B).
The eﬀect of each modiﬁed LDL on the enzymatic activity of eNOS
within the HCAEC was measured by quantiﬁcation of the conversion of
3H-arginine to 3H-citrulline. Incubation of the HCAEC with HOCl- or
HOSCN-modiﬁed LDL resulted in a decrease in 3H-citrulline formation,
consistent with reduced eNOS activity (Fig. 2D). The decrease in ac-
tivity was dependent on the concentration of oxidant used to modify the
LDL and was more marked with HOSCN-modiﬁed LDL compared to
HOCl-modiﬁed LDL (Fig. 2D). In this case, the decrease in eNOS activity
was greater with the modiﬁed LDL compared to that seen in the cor-
responding experiments with the incubation control LDL (Fig. 2D).
To conﬁrm that the decrease in NO• production and eNOS activity
was not related to cytotoxic eﬀects of each modiﬁed LDL, we examined
the viability of the HCAEC following exposure to each LDL for 24 h as
described above. No change in viability was observed by assessing ei-
ther LDH leakage (black bars) or alterations in metabolic activity by
MTT assay (white bars) (Fig. 3). Taken together, these data are con-
sistent with reduced capability for eNOS to synthesise NO• after treat-
ment with HOSCN- and HOCl-modiﬁed LDL that is independent of
perturbations in cell viability.
3.3. Eﬀect of modiﬁed LDL on eNOS expression, post-translational
modiﬁcation, coupling and O2•- production in HCAEC
To examine the pathways involved in the modiﬁed LDL induced loss
in eNOS activity and NO• production, eNOS mRNA and protein ex-
pression were assessed by qRT-PCR and Western blotting, respectively.
No change in the expression of eNOS mRNA was observed on exposure
of HCAEC to control LDL or HOCl-modiﬁed LDL for 3 or 24 h (Fig. 4A).
In contrast, treatment of HCAEC with HOSCN-modiﬁed LDL for 3 and
24 h resulted in an unexpected increase in the expression of eNOS
mRNA (Fig. 4A). Western blotting studies were also performed to assess
Fig. 1. Modiﬁed LDL compromises vasorelaxation in rat aortic rings. Vasorelaxation
dose-response curves of rat aortic ring after incubation with control LDL, HOSCN- or
HOCl-modiﬁed LDL for 1 h. (A) Representative example of a myographic trace of rat
aortic ring vasoconstricted with increasing doses of NE (5 × 10−7–1 × 10−4 M) and
vasodilated with increasing doses of ACh (1 × 10−7–1 × 10−4 M). (B, C) Rat aortic
segments pre-constricted with NE and relaxation assessed by accumulative dose of (B)
ACh (10−9–10−3 M) and (C) SNP (10−9–10−5 M). Symbols represent (●) control, (□)
control LDL, (▽) LDL modiﬁed by HOSCN (250 µM, 24 h) and (▲) LDL modiﬁed by
HOCl (250 µM, 24 h). Non-linear dose-response curves; (solid line) control, (dashed line)
control LDL, (dotted line) HOSCN-LDL and (dashed and dotted line) HOCl-LDL. Data
represent the mean±SEM (n = 5). Two-way ANOVA with Dunnett's multiple compar-
ison test. * and ** represents signiﬁcant diﬀerence (p<0.05 and 0.01, respectively)
between HOSCN-modiﬁed LDL compared to the control. ## represents signiﬁcant dif-
ference (p<0.01) between HOCl-modiﬁed LDL compared to the control.
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the eﬀect of modiﬁed LDL treatment on the protein levels of eNOS and
the extent of eNOS phosphorylation, which plays a key role in eNOS
activation and inﬂuences NO• production [11,15]. However, no sig-
niﬁcant changes in either total eNOS protein or eNOS phosphorylation
(at S1177) relative to a β-actin loading control were observed on
treatment of HCAEC with any of the LDL preparations for short (< 3 h)
or extended (24 h) incubation times (Figs. 4B, 4C).
To further examine eNOS functionality, the ratio of protein dimer:
monomer expression was assessed. Treatment of HCAEC with HOSCN-
modiﬁed LDL resulted in a signiﬁcant decrease in the dimer: monomer
ratio of eNOS compared to the non-treated control cells, or cells ex-
posed to the incubation control LDL (Fig. 4D). A decrease in the dimer:
monomer was also seen in the experiments with HOCl-modiﬁed LDL,
but in this case, the changes were not signiﬁcant compared with either
the non-treated control or incubation control LDL samples (Fig. 4D).
Uncoupling of eNOS results in the disruption of the electron
transport from the reductase domain of the enzyme, which decreases
NO• production owing to the direct reduction of O2 to O2•- and ele-
vated formation of peroxynitrite [12]. Alterations in the production
of O2•- by HCAEC exposed to each modiﬁed LDL were therefore ex-
amined by measuring the formation of 2-OH-E+ by HPLC following
addition of DHE to the cells. However, no change in the concentra-
tion of 2-OH-E+ was observed on addition of DHE to HCAEC treated
with either HOCl- or HOSCN-modiﬁed LDL for 24 h, compared to the
non-treated cells (Fig. 5). In contrast, exposure of the HCAEC to
menadione (50 μM) for 30 min as a positive control resulted in the
detection of a signiﬁcant increase in the formation of 2-OH-E+,
consistent with elevated O2•- production (Fig. 5). This suggests that
the production of O2•- by HCAEC is not inﬂuenced by treatment with
modiﬁed LDL under the conditions employed in this study. The
Fig. 2. Treatment of HCAEC with modiﬁed LDL decreases NO• production and eNOS activity. (A) Representative EPR spectra of Fe-MGD-NO adducts showing production of NO• by
HCAEC over 36 min at 37 °C in control cells (spectrum 1) and after treatment of the cells with either incubation control LDL (spectrum 2), HOSCN-modiﬁed LDL (100 μM HOSCN,
spectrum 3; 250 μM HOSCN, spectrum 4) or HOCl-modiﬁed LDL (100 μM HOCl, spectrum 5; 250 μM HOCl, spectrum 6) with cells exposed to each LDL (0.1 mg mL−1) for 24 h. (B) EPR
spectra from HCAEC as in (A) but in control cells in the presence and absence of the eNOS inhibitor L-NIO (100 µM). (C) Graph showing the EPR signal area (AUC; area under the curve)
assessed by double integration of the Fe-MGD-NO spectra as a measure of relative NO• production. (D) Graph showing eNOS activity in HCAEC treated with each modiﬁed LDL as for (A),
measured by the conversion of 3H-arginine to 3H-citrulline. Data in (C) and (D) represent mean± SEM of n ≥ 3 with *, ** and *** showing signiﬁcance compared to the non-treated
control with p<0.05, 0.01 and 0.001, respectively, by one-way ANOVA with Dunnett's post hoc test.
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Fig. 3. No change in viability on treatment of HCAEC with modiﬁed LDL for 24 h.
HCAEC were incubated in the absence and presence of incubation control LDL, LDL
modiﬁed by HOSCN (250 µM, 24 h) or LDL modiﬁed by HOCl (250 µM, 24 h). HCAEC
viability (LDH assay; black) and metabolism (MTT assay; white) was determined after
24 h treatment with LDL (0.1 mg mL−1). Data represent mean± SEM of n ≥ 3 with no
signiﬁcant alterations in viability seen between control and LDL treatments by one-way
ANOVA with Dunnett’s post hoc test.
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Fig. 4. Eﬀect of modiﬁed LDL on eNOS expression, phosphorylation and coupling in HCAEC. (A) eNOS gene expression after treatment of HCAEC with each modiﬁed LDL
(0.1 mg mL−1) for 3 h (white bars) or 24 h (black bars) normalised to 18S and B2M housekeeping genes. (B, C) Western blot analysis of eNOS, eNOS phosphorylation (at S1177) and β-
actin in HCAEC after 24 h treatment with each modiﬁed LDL. Graphs show densitometry of (B) total eNOS relative to β-actin and (C) phosphorylated eNOS relative to total eNOS. (D)
Western blot analysis of the uncoupling of eNOS in HCAEC treated with modiﬁed LDL for 24 h as measured by the ratio of dimer: monomer bands assessed by densitometry. Data
represent mean±SEM of n≥ 3 with *, ** and *** showing signiﬁcance compared to the non-treated control with p<0.05, 0.01 and 0.001, respectively, with # and ## representing
p<0.05 and 0.01 compared to incubation control LDL using one-way ANOVA with Dunnett's (A) or Sidak's (B–D) post hoc test.
Fig. 5. No change in O2•- production in HCAEC exposed to
each modiﬁed LDL. The production of O2•- was measured over
30 min at 37 °C following addition of DHE (50 μM) to HCAEC (0.5
x 105 cells mL-1) treated with in the absence (black bars) or pre-
sence (white bars) of each modiﬁed LDL (0.1 mg mL-1 apoB100)
for 24 h. Panel (A) shows HPLC trace from the ﬂuorescence de-
tector (DHE; λex 358 nm, λem 440 nm, and 2-OH-E+ and E+;
λex 490 nm, λem 565 nm) from control cells. Panel B shows 2-
OH-E+ concentration normalised to cellular protein from non-
treated, incubation control LDL, HOSCN-modiﬁed LDL (250 μM
HOSCN), HOCl-modiﬁed LDL (250 μM HOCl) and cells treated
with menadione (MD, 50 µM). Data represent mean± S.E.M. of n
= 3. *** show p<0.001 comparing MD treatment to the non-
treated control cells by one-way ANOVA with Dunnett’s post hoc
test.
A.I. Abdo et al. Redox Biology 13 (2017) 623–632
628
extent of 3-nitro-Tyr formation on HCAEC proteins following treat-
ment of the cells with each modiﬁed LDL was also measured by
Western blotting to assess alterations in the production of perox-
ynitrite. However, no evidence was obtained for any alteration in the
extent of 3-nitro-Tyr formation, suggesting that there is no sig-
niﬁcant alteration in peroxynitrite formation in HCAEC exposed
HOCl- or HOSCN-modiﬁed LDL (data not shown).
3.4. Eﬀect of modiﬁed LDL on the colocalization of eNOS with caveolin-1
The activity of eNOS can be inﬂuenced by caveolin-1 [14], with
previous studies in HUVEC showing that HOCl-modiﬁed LDL can de-
crease the interaction of eNOS with caveolin-1 [5]. Therefore, we as-
sessed whether exposure of HCAEC to each modiﬁed LDL inﬂuenced
caveolin-1 and eNOS colocalisation. Compared to control LDL treated
HCAEC, redistribution of eNOS and caveolin-1 was apparent in HCAEC
exposed to modiﬁed LDL, particularly HOCl-treated LDL, with more
punctate staining of colocalised eNOS and caveolin-1 apparent within
the cytosol following treatment (Fig. 6: white arrows).
The colocalisation of eNOS and caveolin-1 in the HCAEC exposed to
each modiﬁed LDL was examined further by Western blotting following
immunoprecipitation using an antibody against eNOS. This im-
munoprecipitation resulted in the detection of similar amounts of eNOS
in the lysates of HCAEC regardless of the presence of control or mod-
iﬁed LDL (Fig. 7A). However, no evidence was obtained for coimmu-
noprecipitation of caveolin-1 using this technique despite the presence
of caveolin-1 in cell lysates prior to the immunoprecipitation step
(Fig. 7B).
4. Discussion
It is well established that oxLDL can disrupt the endothelial pro-
duction of NO•, which impairs endothelium-dependent vasodilation
[8–10]. However, the speciﬁc pathways responsible for these eﬀects in
vivo are not well deﬁned, as oxLDL can inﬂuence eNOS expression and
functionality through a number of divergent pathways, which are de-
pendent on the extent and nature of LDL modiﬁcation and the type of
endothelial cell under study. Few studies have assessed the reactivity of
LDL modiﬁed by MPO and/or HOCl with endothelial cell, despite evi-
dence for the presence of this type of oxLDL in both the diseased tissue
Fig. 7. No interaction of caveolin-1 and eNOS following co-immunoprecipitation.
HCAEC were treated with each modiﬁed LDL (0.1 mg mL−1) for 24 h, before lysis and
immunoprecipitation with a monoclonal antibody raised against eNOS. Immunoblotting
(IB) experiments were performed with eNOS and caveolin-1 antibodies on the im-
munoprecipitate (IP) and lysate supernatant with lane 1: no LDL, lane 2: control LDL, lane
3: LDL modiﬁed by HOSCN (250 µM, 24 h), lane 4: LDL modiﬁed by HOCl (250 µM, 24 h).
Data are representative of 3 independent experiments.
Fig. 6. eNOS and caveolin-1 localisation in HCAEC following treatment with modiﬁed LDL. Localisation of eNOS and caveolin-1 was assessed in HCAEC after treatment with each
modiﬁed LDL (0.1 mg mL−1) for 24 h by immunoﬂuorescence. Columns represent diﬀerent treatments with (1) non-treated control; (2) control LDL; (3) LDL modiﬁed with HOSCN
(250 µM, 24 h) and (4) LDL modiﬁed with HOCl (250 µM, 24 h). The rows show staining for the nucleus (DAPI; blue), caveolin-1 (green), eNOS (red) and the merged image from nucleus,
caveolin-1 and eNOS. White arrows indicate colocalised speckling of eNOS and caveolin-1 in HCAEC treated with LDL modiﬁed by either HOSCN or HOCl. Data are representative of 3
independent experiments.
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and circulation of patients with atherosclerosis [21,27]. Similarly, the
eﬀects of LDL modiﬁed by the other major MPO-derived oxidant,
HOSCN, on endothelial function remain to be established. This is sig-
niﬁcant in light of data correlating plasma SCN- (the precursor of
HOSCN) with foam cell formation and other early markers of athero-
sclerosis in smokers [34,35]. In this study, we show for the ﬁrst time
that LDL modiﬁed by HOSCN alters the mRNA expression and func-
tionality of eNOS, and induces a decrease in both the endothelial pro-
duction of NO• and the extent of vasorelaxation in pre-constricted aortic
rings. The eﬀect of HOSCN-modiﬁed LDL on eNOS activity and NO•
production are similar to, or greater than, that seen in the corre-
sponding experiments with HOCl-modiﬁed LDL.
Treatment of HCAEC with HOCl- and HOSCN-modiﬁed LDL resulted
in a decrease in eNOS activity and NO• production, which was asso-
ciated with uncoupling of the enzyme, rather than altered expression or
post-translational modiﬁcation, such as phosphorylation of Ser1177,
which has been shown previously to be sensitive to other types of
oxLDL (e.g. [18]). Importantly, a signiﬁcant reduction in aortic dis-
tensibility was observed in rat aortic rings after incubation with
HOSCN- and HOCl-modiﬁed LDL ex vivo. HOSCN- and HOCl-modiﬁed
LDL reduced endothelium-dependent (ACh-induced) signalling to im-
pair the arterial distensibility, but did not alter aortic relaxation in-
duced by SNP. This is consistent with impaired arterial distensibility
being due to eﬀects on the endothelium and rather than the smooth
muscle, in agreement with previous studies with other types of oxLDL
[9,10].
Treatment of HCAEC with HOSCN-modiﬁed LDL, but not HOCl-
modiﬁed LDL, resulted in an increase in eNOS mRNA expression,
though this was not reﬂected in the protein levels, when measured by
Western blotting. This may be associated with an increased extent of
LDL lipid oxidation, and the formation of linoleate-derived oxidation
products, which is observed on exposure of LDL to HOSCN but not
HOCl under the conditions employed in this study [38]. Thus, it has
been shown previously that oxidised linoleate products, including 13-
hydroperoxyoctadecadienoate (13-HPODE) cause a dose-dependent
increase in eNOS mRNA levels following exposure to bovine arterial
endothelial cells over 24 h [49]. However, 13-HPODE also increased
protein expression and enzyme activity [49], which was not observed
with HOSCN-modiﬁed LDL. This may reﬂect parallel post-transcrip-
tional regulatory mechanisms, such as eNOS antisense RNA, which
could prevent the translation of eNOS protein by compromising eNOS
mRNA stability [50]. Alternatively, a number of microRNAs are re-
ported to post-transcriptionally regulate eNOS expression, such as
miRNA-24 [51] and 27nt-miRNA [52], which has not been examined in
the current study.
With HOSCN- and HOCl-modiﬁed LDL, the changes in eNOS activity
in HCAEC were independent of alterations to viability, when measured
by LDH release or metabolic activity, but correlated with the extent of
eNOS uncoupling, assessed by measuring the eNOS monomer:dimer
ratio using Western blotting. Although the extent of uncoupling agreed
well with the decreased eNOS activity and NO• production, no change
in O2•- production was apparent on measuring the formation of 2-OH-
E+ by addition of DHE to the HCAEC and HPLC analysis. The reason for
this is not certain, but it does not appear to be related to consumption of
the O2•- by NO• to form the potent oxidant ONOO-, as no evidence was
obtained for any alteration in the formation of 3-nitroTyr (a biomarker
of ONOO- reactivity) in HCAEC under these experimental conditions.
That there is no change in the HCAEC production of O2•- on in-
cubation with the modiﬁed LDLs, suggests that stimulation of O2•-
production may not be the cause of eNOS uncoupling, in contrast to
studies with other types of oxLDL (e.g. [17,53]). Perturbations in O2•-
production in cells exposed to oxLDL leading to eNOS uncoupling have
been attributed to scavenger receptor binding, particularly to LOX-1
(reviewed [54]), and it is well established that various types of oxLDL
can trigger activation of mitogen activated protein kinase (MAPK) and
protein kinase C (PKC) pathways, which can inﬂuence eNOS
phosphorylation as well as altering O2•- production [17,18]. Whether
these pathways play a role in the altered NO• production seen in HCAEC
exposed to HOSCN- and HOCl-modiﬁed LDL is not certain, though no
changes in eNOS phosphorylation were apparent. Similarly, no changes
are seen in scavenger receptor expression or modiﬁed LDL uptake on
comparison to control LDL (data not shown).
The enzymatic activity of eNOS relies on tetrahydrobiopterin (BH4)
to bind haem and L-Arg to produce NO• [55]. Similarly, O2•- production
by uncoupled eNOS can be dependent on the BH4/BH3• ratio, in-
dependently of the L-Arg concentration [56]. In the catalytic process,
BH4 is oxidised to BH3• radical, which can be recovered to BH4 with
ascorbate and eNOS itself in a BH4/BH3• redox cycle [57]. However, if
eNOS coupling is impaired as we have shown by HOSCN-modiﬁed LDL
and to a lesser extent with HOCl-modiﬁed LDL, depletion or displace-
ment of BH4 may be an important factor in modulating eNOS activity in
MPO-oxidant modiﬁed LDL. Levels of BH4 and BH3• in the loss of eNOS
activity seen in the HCAEC exposed to modiﬁed LDL was not assessed,
however this was not involved in the loss of eNOS activity seen in
HUVEC exposed to HOCl-modiﬁed LDL [5].
It has been demonstrated in experiments with Cu2+-modiﬁed LDL
that decreased availability of L-Arg by an acute increase in arginase II
activity and expression also contributes to decreased eNOS activity in
HCAEC, as L-Arg catabolism by arginase II is almost 200-fold greater
than that by eNOS [58]. This pathway was also shown to inﬂuence NO•
production in isolated aortic segments [58]. It is not clear if HOSCN- or
HOCl-modiﬁed LDL perturb arginase expression in HCAEC, but it is
worth noting that the nature and extent of modiﬁcation seen on ex-
posure of LDL to Cu2+ is very diﬀerent to that seen with MPO oxidant
modiﬁed LDL. Moreover, it is not clear as to what eﬀect exposure of
HCAEC to native LDL has on arginase activity [58].
An increase in caveolin-1 expression has been implicated as a
pathway to eNOS activity impairment, with the ability of HOCl-mod-
iﬁed LDL to perturb eNOS activity in HUVECs also associated with the
translocation of the eNOS from the plasma membrane and Golgi to
other cellular compartments rather than uncoupling [5]. This redis-
tribution of eNOS was attributed to the induction of changes to the
physicochemical properties of the membranes, which occurred in-
dependently of eNOS myristoylation or palmitoylation [5], which is
also observed with Cu2+-modiﬁed LDL [6,59]. In the latter case, the
internalisation of eNOS is related to depletion of cholesterol in the
caveolae, which could be prevented by blocking oxLDL binding to the
CD36 scavenger receptor [59], which could be important with HOCl-
modiﬁed LDL that is known to bind to this receptor, in HUVEC at least
[60]. Similarly, high-density lipoprotein (HDL) was able to recover
eNOS localisation at the caveolae following delocalisation by oxLDL
[59]. This was attributed to HDL donating cholesterol to the caveolae
membrane [59].
In HCAEC, our data support some alteration to the localisation of
eNOS, which was more pronounced on exposure of the cells to HOCl-
modiﬁed LDL. By immunoﬂuorescence, the eNOS appeared to coloca-
lise with caveolin-1, in contrast to data from HUVEC, where there was
no alteration in caveolin-1 localisation [5]. However, caveolin-1 did not
colocalise with eNOS in immunoprecipitation experiments. This may
reﬂect a disruption in the interaction between the two proteins re-
sulting from the experimental conditions used to precipitate and re-
solubilise the cell lysates for analysis. Further experiments are required
to fully assess the eﬀects of HOSCN- and HOCl-modiﬁed LDL on both
the scavenger receptor binding and membrane cholesterol content, and
deﬁne the cellular pathway responsible for uncoupling. A limitation of
the current study is that O2•- production was measured for a deﬁned
period of time (30 min) following 24 h treatment of HCAEC with
modiﬁed LDL, rather than during treatment. Thus, it is possible that
increased O2•- production could play a role in the eNOS uncoupling
observed here, particularly as altered ROS ﬂuxes can occur very rapidly
after exposure of endothelial cells to other types of oxLDL [54].
Overall, these data show that both HOSCN- and HOCl-modiﬁed LDL
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decrease NO• production, which directly aﬀects arterial distensibility in
functioning tissue by inducing endothelial dysfunction. That the extent
of decreased NO• production and vasorelaxation was comparable on
modiﬁcation of LDL by HOSCN and HOCl is signiﬁcant, as it has been
suggested that SCN- may slow lesion development in atherosclerosis, as
HOSCN-LDL is not taken up by macrophages to the same extent as
HOCl-LDL [27,38]. This has potential implications for smokers who
have elevated plasma levels of SCN-, and show evidence of increased
endothelial dysfunction. This study also highlights the importance of
additional mechanistic studies to better understand how supplementa-
tion with SCN- to promote HOSCN rather than HOCl formation inﬂu-
ences disease progression, including atherosclerosis, during chronic
inﬂammation.
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